Boothbay Fund Management, LLC Bluebird Bio, Inc. Transaction History

Boothbay Fund Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.14 - $8.22 $220,459 - $577,126	-70,210 Reduced 49.22%	72,427 $230,000
Q4 2022 Feb 14, 2023	BUY	$5.77 - $8.49 $351,127 - $516,650	60,854 Added 74.41%	142,637 $987,000
Q3 2022 Nov 14, 2022	BUY	$3.75 - $7.39 $306,686 - $604,376	81,783 New	81,783 $518,000
Q1 2021 May 17, 2021	SELL	$16.59 - $33.89 $86,467 - $176,634	-5,212 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$27.5 - $37.92 $143,330 - $197,639	5,212 New	5,212 $226,000
Q3 2020 Nov 16, 2020	SELL	$34.44 - $43.75 $261,985 - $332,806	-7,607 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $206,301 - $349,693	7,607 New	7,607 $464,000
Q1 2019 May 15, 2019	SELL	$64.44 - $104.11 $177,016 - $285,990	-2,747 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$59.1 - $93.26 $162,347 - $256,185	2,747 New	2,747 $273,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.